Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed. I thought stock buyback would goose the price. I sold everything last year. Was waiting to get in if price fell to .80 in anticipation of buyback. If income is going down and margins tightening, the buyback will have little impact. Buyback should be supported by cash flow and profits. I may get back in if it falls below .60 with the intent to sell at .70 at first opportunity. Which will likely be the price move up a week prior to Q report. Same way I sold last year. Will be a much smaller position than what I originally had.
I just discovered the Full View New button. Still takes time to load bit I can scroll through all messages quickly.
OT....Ihub running slow for anyone else? Several seconds for me to move from one post to another.
Cap, have you ever asked Dr Bhatt if he has seen patients on generics that have results that do not support reduce it and V results?
Did you start V in response to the cancer? What initiated it? Doctor advice, something you researched, etc,,,?
Thought they had a superbowl commercial pre-Du, we got the beat tune. Did it do much for sales back then? With a sales force also.
By share count, mtnb is my largest holding. I have not seen any mention of lymph system work or amrn. Fungal infections, cancer, inflammation is mentioned on their latest slide deck. They could partner with amrn, since it is a delivery system. But no mention of amrn to this point.
Still waiting for mtnb to announce a funding solution for a p3 fungal study, and to continue operations into next year. So perhaps amrn is the long awaited partner announcement. But i think it is a longshot.
Looks like Berg and Ketchum were the other Form 4s
I found this pressing the ihub quote button and looking under amarin news.
https://ichgcp.net/clinical-trials-registry/NCT02719327
Came across this site. Shows some update for December 2023, but does not provide any information with regard to results.
NS, is this information useful, or, what you have shared before? The Springer link, pg 39 of the pdf.
https://www.google.com/search?q=brave+lp019&oq=brave+lp019&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRg9MgcIAhAhGKABMgcIAxAhGKABMgcIBBAhGKAB0gEINzI0OWoxajSoAgCwAgA&client=ms-android-verizon-us-rvc3&sourceid=chrome-mobile&ie=UTF-8
Lot of numbers with regard to Results, does not mean much to me. PG 39 of the pdf.
Cap, based on your self experiment with generic epa, I suggest you change your catch phrase to "It's the VASCEPA stupid".
Then every solar, battery and electric vehicle company that benefited from Biden's green initiatives should be very worried.
I believe the company will try to get the new formulation approved for alzheimers, not vascepa. Stack up patents for vascepa for the indication, but will not move forward with fda approval. My guess and opinion, nothing to back it up.
Thanks for that article. Great information that is not another derivative of RI data.
My hope is he plans to get it back quickly with a substantial payback.
I had same thought. Do the price thresholds increase if there is a reverse spli?
Click on the name
click on more
click on ignore.
Has worked several times for me without a paid subscription.
Today, amrn has lost the least of the few biomeds I follow. vktx, agen, crmd, bngo, all down 5% or more. Not sure what it means. Whoever can drive amrn down can also suspend it?
Is it possible that meeting was delayed to add another voting item?
Such as a proposed buy out?
Amarin website lists 6 openings, all in Europe.
I decided to vote for the Denner crew based on the subscription model arrangement proposed in one of the pre-vote mailings. If implemented, it would be a significant change to how V sales are managed. Will it be successful, I do not know. But, it is quite a change from prior management.
I was not satisfied with the progress prior management was achieving. Lot of lawsuits, lot of free shares, not much profit, questionable future prospects.
Would not be surprised if previous board held back some financials, allowing last quarter to be profitable. Like paying bills on time. Those financials will now show up on this quarter.
Believe a magistrate judge is viewed as an assistant to the district judge.
https://en.m.wikipedia.org/wiki/United_States_magistrate_judge
Got through my DRL script, which Express Scripts and BCbS of IL had used to replace my Vascepa. Called my PA and asked for new script, with Vascepa only. Just received my meds. Name brand Vascepa, and cost to me was the same it has been for the past few years, $100 for 90 day supply.
NORTH I did not look very hard. Stopped when I found this article on Amylin. Icahn identified as a dissident shareholder.
[url][/url][tag]https://www.sandiegouniontribune.com/sdut-amylin-board-directors-appoints-new-chairman-2009aug25-story.html[/tag]
I agree, and have said similar before, there is not a measurable to monitor the effectiveness.
All great points to the replies I received. And I agree with the health benefits, always have.
Still comes down to revenue and profit. I am jaded by the mediocre results of the past 1 to 2 years. So, what does each party foresee in revenue and profits to make this fight worthwhile?
I keep asking myself the same question, for both sides. What do they each see that is so promising to make it worth the fight? I feel like both sides are holding back on something.
Thought FFS posted yesterday that there were better opportunities elsewhere.
PDude addressed this several days ago.
If there was not any difference, would you expect management to share test results publicly? Or to even say an analysis had been performed?
Looks like votes are being monitored. I have 4 emails this morning with ballot for the white card. I have already voted blue earlier in the week. These cards say:
The last vote recorded on your account was submitted using a different voting instruction card. If you submit a new vote below, your previous instructions will be revoked. If this is unclear or if you need further clarification, please contact the person that services your account for assistance.
I learned a new word from this newest version, canonically. Thought that was classy.
I also received 4 of each in my email this morning.
I wrote DF King about the blue proxy card or electronic control number and my TDA accounts. The reply I got a few minutes ago below.
TD Ameritrade uses Broadridge Financial Services to distribute proxy material to its clients.
Broadridge has indicated that it will be mailing Sarissa's proxy materials tomorrow (including the BLUE voting instruction form).
Holders who have signed up for electronic delivery of materials with their brokers will receive an email notification on Tuesday night.
Both the email and the hard copy BLUE voting instruction form will have your control number and the URL to the voting website to cast your vote.
As will I, per Sarissa's instructions.
Sounds like the vote tally will be based on the For's tally for each card. Makes me wonder if the Againsts are a non-vote.
Only thing missing is the board and management failure to support Marjac shareholder lawsuit.
I keep coming back to this question, what is the key measurable for determining the effectiveness of ipe? Statins have a couple measurable that are used to correlate drug results with cvd. These measurable are well known. Most other drugs have a measurable that determine effectiveness of treatment in a short time.
It is my understanding that triglycerides are not a accepted measurable of cvd risk. What other measurable are there then? What gives doctors, insurers and patients insight into the rewards for investing in this medication?
I am voting all blue card for Sarissa. European roll out under this mgt and bod has not been impressive. Even the UK rollout looked borderline failure until Dr Bhatt stepped in.
My hope is that Sarissa sees this measurable issue and plans to rectify it. Realize that hope is a poor strategy, because hope has not worked with current bod team.
I have been taking DRL for 6 weeks. Do not know if it is psoriasis or extremely dry skin. Either way, past 7 days I have noticed it, several white scaly patches that flake. Arms and upper lip. Condition I have not had before. I plan to stop taking the DRL for a couple weeks, see if this clears.
What puzzles me, with regard to the HN situation, is there has not been any announcement or information with regard to challenging other insurance companies. AMRN pr'd the Hikma lawsuit, then the addition of HN in 2021. I had hoped they would have taken an aggressive approach with the other insurers and pr'd their intention to vigorously defend infringement on the cvd patents.